A Phase I Study to Evaluate the Pharmacokinetics and Safety of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib With Trametinib in Chinese Subjects With Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 25 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 23 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2018.